Michael King
Stock Analyst at Rodman & Renshaw
(1.31)
# 3,665
Out of 5,246 analysts
103
Total ratings
38.53%
Success rate
-6.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BTAI BioXcel Therapeutics | Initiates: Buy | $17 | $1.13 | +1,404.42% | 1 | Mar 17, 2026 | |
| KPTI Karyopharm Therapeutics | Initiates: Buy | $28 | $8.16 | +243.14% | 1 | Mar 10, 2026 | |
| ELTX Elicio Therapeutics | Initiates: Buy | $17 | $9.95 | +70.85% | 1 | Mar 10, 2026 | |
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $14.09 | +4,514.84% | 4 | Apr 1, 2024 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $3.50 | +214.29% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.42 | +2,153.52% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $0.903 | +7,485.83% | 10 | Jun 12, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $0.4436 | +1,771.06% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $638.88 | +34.92% | 11 | May 1, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $24 | $50.15 | -52.14% | 10 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $166 | $3.11 | +5,237.62% | 8 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $11.31 | +271.35% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $297.45 | +2.20% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $12.60 | +820.63% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.07 | +397.58% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $48.13 | -50.14% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $59.71 | -22.96% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $28.14 | +241.15% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $504 | $8.28 | +5,986.96% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $32.67 | -5.11% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $806.46 | -95.54% | 2 | Nov 13, 2017 |
BioXcel Therapeutics
Mar 17, 2026
Initiates: Buy
Price Target: $17
Current: $1.13
Upside: +1,404.42%
Karyopharm Therapeutics
Mar 10, 2026
Initiates: Buy
Price Target: $28
Current: $8.16
Upside: +243.14%
Elicio Therapeutics
Mar 10, 2026
Initiates: Buy
Price Target: $17
Current: $9.95
Upside: +70.85%
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $14.09
Upside: +4,514.84%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $3.50
Upside: +214.29%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.42
Upside: +2,153.52%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $0.903
Upside: +7,485.83%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $0.4436
Upside: +1,771.06%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $638.88
Upside: +34.92%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $50.15
Upside: -52.14%
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $3.11
Upside: +5,237.62%
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $11.31
Upside: +271.35%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $297.45
Upside: +2.20%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $12.60
Upside: +820.63%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $2.07
Upside: +397.58%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $48.13
Upside: -50.14%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $59.71
Upside: -22.96%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $28.14
Upside: +241.15%
Jan 10, 2022
Initiates: Buy
Price Target: $504
Current: $8.28
Upside: +5,986.96%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $32.67
Upside: -5.11%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $806.46
Upside: -95.54%